Amy L. Salisbury
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Amy L. Salisbury has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Alyse Laliberte
Alpert Medical School of Brown University, Women & Infants' Hospital, Providence, RI 02905
1 shared publication - Barry M. Lester
Brown Center for the Study of Children at Risk; Department of Pediatrics; Women & Infants Hospital of Rhode Island; Providence, RI USA; Department of Psychiatry; Warren Alpert Medical School of Brown University; Providence, RI USA; Department of Pediatrics; Warren Alpert Medical School of Brown University; Providence, RI USA
1 shared publication - Bethany McGonnigal
Alpert Medical School of Brown University, Women & Infants' Hospital, Providence, RI 02905
1 shared publication - Gabriele Fischer
Medical University of Vienna
1 shared publication - Hendree E. Jones
Department of Obstetrics and Gynecology University of North Carolina School of Medicine Chapel Hill North Carolina USA
1 shared publication - James F. Padbury
Alpert Medical School, Brown University
1 shared publication
Latest Publications
- Open Access
- 1 April 2018
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 185, 40-49
Prenatal exposure to methadone or buprenorphine: Early childhood developmental outcomes
- 1 April 2018
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 185, 40-49
Open AccessPrenatal exposure to methadone or buprenorphine: Early childhood developmental outcomes
- 5 May 2011
- Published by Wiley in Developmental Psychobiology
- Vol. 53 (7) , 711-723
Maternal depression and anxiety are associated with altered gene expression in the human placenta without modification by antidepressant use: Implications for fetal programming
We sought to determine if maternal depression, anxiety, and/or treatment with selective serotonin reuptake inhibitors (SSRIs) affect placental human serotonin transporter (SLC6A4), norepinephrine transporter (SLC6A2), and 11β‐hydroxysteroid dehydrogenase type 2 (11β‐HSD2) gene expression. Relative mRNA expression was compared among placental samples (n = 164) from healthy women, women with untreated depression and/or anxiety symptoms during pregnancy, and women who used SSRIs. SLC6A4 expression was significantly increased in placentas from women with untreated mood disorders and from women treated with SSRIs, compared to controls. SLC6A2 and 11β‐HSD2 expression was increased in noncontrol groups, though the differences were not significant. SLC6A4, SLC6A2, and 11β‐HSD2 expression levels were positively correlated. The finding that maternal depression/anxiety affects gene expression of placental SLC6A4 suggests a possible mechanism for the effect(s) of maternal mood on fetal neurodevelopmental programming. SSRI treatment does not further alter the elevated SLC6A4 expression levels observed with exposure to maternal depression or anxiety. © 2011 Wiley Periodicals, Inc. Dev Psychobiol 53:711–723, 2011.
- 5 May 2011
- Published by Wiley in Developmental Psychobiology
- Vol. 53 (7) , 711-723
Maternal depression and anxiety are associated with altered gene expression in the human placenta without modification by antidepressant use: Implications for fetal programming
We sought to determine if maternal depression, anxiety, and/or treatment with selective serotonin reuptake inhibitors (SSRIs) affect placental human serotonin transporter (SLC6A4), norepinephrine transporter (SLC6A2), and 11β‐hydroxysteroid dehydrogenase type 2 (11β‐HSD2) gene expression. Relative mRNA expression was compared among placental samples (n = 164) from healthy women, women with untreated depression and/or anxiety symptoms during pregnancy, and women who used SSRIs. SLC6A4 expression was significantly increased in placentas from women with untreated mood disorders and from women treated with SSRIs, compared to controls. SLC6A2 and 11β‐HSD2 expression was increased in noncontrol groups, though the differences were not significant. SLC6A4, SLC6A2, and 11β‐HSD2 expression levels were positively correlated. The finding that maternal depression/anxiety affects gene expression of placental SLC6A4 suggests a possible mechanism for the effect(s) of maternal mood on fetal neurodevelopmental programming. SSRI treatment does not further alter the elevated SLC6A4 expression levels observed with exposure to maternal depression or anxiety. © 2011 Wiley Periodicals, Inc. Dev Psychobiol 53:711–723, 2011.